Operating
Change in Accrued Liabilities
Vertex Pharmaceuticals Change in Accrued Liabilities decreased by 299.6% to -$664.50M in Q4 2025 compared to the prior quarter.
Analysis
StatementCash Flow Statement
SectionOperating
CategoryLiquidity
SignalContext dependent
VolatilityModerate
First reportedQ1 2007
Last reportedQ3 2025
How to read this metric
An increase represents a source of cash through deferred payment, while a decrease represents a cash outflow as obligations are settled.
Detailed definition
Reflects the change in obligations for expenses incurred but not yet invoiced or paid, such as employee compensation, ta...
Peer comparison
Standard operating cash flow component found in almost all corporate financial statements.
Metric ID:
cf_change_in_accrued_liabilitiesHistorical Data
16 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$45.46M | $146.63M | $51.24M | $61.60M | $485.50M | $433.20M | $140.70M | $276.70M | $368.70M | $194.10M | $168.30M | $170.60M | $48.10M | $166.60M | $332.90M | -$664.50M |
| QoQ Change | — | +422.6% | -65.1% | +20.2% | +688.1% | -10.8% | -67.5% | +96.7% | +33.2% | -47.4% | -13.3% | +1.4% | -71.8% | +246.4% | +99.8% | -299.6% |
| YoY Change | — | — | — | — | >999% | +195.4% | +128.4% | -43.0% | -14.9% | +38.0% | -39.2% | -53.7% | -75.2% | -1.0% | +95.1% | — |
Range-$664.50M – $485.50M
CAGR+104.5%
Avg YoY Growth+127.1%
Median YoY Growth-1.0%
Change in Accrued Liabilities at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's change in accrued liabilities?
- Vertex Pharmaceuticals (VRTX) reported change in accrued liabilities of -$664.50M in Q4 2025.
- What does change in accrued liabilities mean?
- The net change in expenses that have been recognized but not yet paid.